Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest ...

Paris, le 12 mars 2025 – MSInsight, start-up innovante spécialisée dans la médecine de précision en oncologie, annonce la réussite de son tour de financement d’amorçage d'un montant de 1,6 million d’e ...

Paris, France (10 mars 2025) - EssilorLuxottica annonce la mise à disposition de son Document d’enregistrement universel 2024 dans les conditions requises par la règlementation en vigueur. La version ...

A key differentiator of this vaccine is its ability to target the entire viral genome, much like the Company’s lead product candidate, TVGN 489. This strategy helps mitigate the risk posed by ...

The Universal Registration Document includes, in particular, the Annual Financial Report, with: the Management Report and the Vigilance Plan, in compliance with articles L.225-100 and L.225-102-1 ...

Under the expert guidance of Integrous Communications, HeartSciences will embark on a comprehensive investor relations program, benefiting from Integrous Communications' proven track record in ...

BioCardia ®, Inc . [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office ...

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading ...

March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the rapidly growing meme coin market ...

Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder ...

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules ...

This €1.6 Million financing will allow MSInsight to finalize MSIcare’s technological development, demonstrate its performance in various types of cancer, and initiate the regulatory clinical ...